Few medications have become as popular and culturally relevant as Ozempic has, but how exactly do it and similar drugs affect ...

For patients with metabolic dysfunction-associated steatotic liver disease (MASLD) and diabetes, glucagon-like peptide 1 ...

GLP-1RA vs insulin use was associated with improved cardiovascular and kidney outcomes among patients with type 2 diabetes on dialysis.

New research shows that metabolic bariatric surgery offers substantial protective benefits for patients with chronic kidney ...

Italy: A recent analysis of the FDA Adverse Event Reporting System (FAERS) database has provided new insights into the safety ...

Wegovy is a brand name for the medication semaglutide. Semaglutide is a glucagon-like peptide-1 receptor agonist (GLP-1RA). This means it makes your body's own glucagon-like peptide-1 hormone, called ...

As Novo Nordisk A/S and Eli Lilly and Co. go head-to-head in the U.S. and Chinese glucagon-like peptide-1 receptor agonists ...

Roche's diversified portfolio and ongoing GLP-1 developments offer decent upside with limited downside. Read more about RHHBY ...

Beijing QL Biopharmaceutical Co., Ltd. ("QL Biopharm"), a clinical stage biopharmaceutical company developing innovative biologic drugs for the treatment of metabolic diseases, today announces that an ...

Amsterdam, Netherlands) A pioneering study, presented today at the European Academy of Dermatology and Venereology (EADV) Congress 2024, demonstrates the significant potential of semaglutide in ...

Following the recent recommendation of its advisory committee, the U.S. FDA gave the nod to Zevra Therapeutics Inc.’s ...